The GLP-1 RAs used by patients in this case series included semaglutide, which is FDA approved as Wegovy® for both adult and adolescent obesity and as Ozempic® for type 2 diabetes in adults, and tirzepatide, which is FDA approved as Zepbound® for adults with obesity. Here, GLP1R is linked to obesity disorder.